Pharmaceutical Venture
Acknowledgement
“Gratitude is the hardest of emotions to express and often does not find adequate ways to convey the entire one feels.”
For this with an ineffable sense of gratitude we take this opportunity to express our deepest sense of indebtedness to Respected Dr. Vidya Hatangadi, Director, of the Gurunanak Institute of Management Studies, who has provided us this opportunity which has helped us to gain insight on the oncology sector in India during our MMS course. At the same time, we want to thank all our faculty members.
We would have never been able to complete our project without the enormous help extended by the whole staff of our college professor of Guru Nanak Institute of Management Studies.
GROUP MEMBERS Sr No. | Roll No. | Name | 1 | A-06 | Harpreet Singh | 2 | A-11 | Karan Doshi | 3 | A-20 | Supriya Hegde | 4 | A-24 | Gurbaani Kaur | 5 | A-27 | Angad Madan | 6 | A-33 | Nandan Masurkar | 7 | A-41 | Neha Panchal | 8 | A-43 | Shruti Pandey | 9 | A-50 | Girish Shetty | 10 | A-58 | Vedant Worlikar | 11 | B-22 | Jidnyasa Kulkarni | 12 | B-33 | Sharan Nottay | 13 | PG-01 | Aalam Musharraf | 14 | PG-12 | Karanvir Gujral |
TABLE OF CONTENTS S.No. | CHAPTERS | PAGE. NO. | | OVERVIEW – INDIAN PHARMACEUTICALINDUSTRY | | 1.1 | Current Scenario | 6 | 1.2 | Major Pharmaceutical Companies | 10 | 1.3 | Government Initiatives | 12 | 1.4 | Oncology Segment | 15 | | LUNG CANCER | | 2.1 | World Scenario | 21 | 2.2 | Indian Scenario | 22 | 2.3 | About Lung Cancer | 30 | 2.4 | Stages of Lung Cancer | 36 | 2.5 | Causes of Lung Cancer | 46 | | LONG LIFE PHARMACEUTICALS PVT. LTD. | | 3.1 | Vision and Mission | 48 | 3.2 | Board of Directors | 49 | 3.3 | Contract Manufacturing | 50 | 3.4 | Suppliers | 53 | 3.5 | Product Range | 56 | 3.6 | Price | 60 | 3.7 | Place | 61 | 3.8 | Promotion | 63 | 3.9 | 5 Force Model | 66 | 4.0 | SWOT Analysis | 69 | 4.1 | PEST Analysis | 71 |
“Gratitude is the hardest of emotions to express and often does not find adequate ways to convey the entire one feels.”
For this with an ineffable sense of gratitude we take this opportunity to express our deepest sense of indebtedness to Respected Dr. Vidya Hatangadi, Director, of the Gurunanak Institute of Management Studies, who has provided us this opportunity which has helped us to gain insight on the oncology sector in India during our MMS course. At the same time, we want to thank all our faculty members.
We would have never been able to complete our project without the enormous help extended by the whole staff of our college professor of Guru Nanak Institute of Management Studies.
GROUP MEMBERS Sr No. | Roll No. | Name | 1 | A-06 | Harpreet Singh | 2 | A-11 | Karan Doshi | 3 | A-20 | Supriya Hegde | 4 | A-24 | Gurbaani Kaur | 5 | A-27 | Angad Madan | 6 | A-33 | Nandan Masurkar | 7 | A-41 | Neha Panchal | 8 | A-43 | Shruti Pandey | 9 | A-50 | Girish Shetty | 10 | A-58 | Vedant Worlikar | 11 | B-22 | Jidnyasa Kulkarni | 12 | B-33 | Sharan Nottay | 13 | PG-01 | Aalam Musharraf | 14 | PG-12 | Karanvir Gujral |
TABLE OF CONTENTS S.No. | CHAPTERS | PAGE. NO. | | OVERVIEW – INDIAN PHARMACEUTICALINDUSTRY | | 1.1 | Current Scenario | 6 | 1.2 | Major Pharmaceutical Companies | 10 | 1.3 | Government Initiatives | 12 | 1.4 | Oncology Segment | 15 | | LUNG CANCER | | 2.1 | World Scenario | 21 | 2.2 | Indian Scenario | 22 | 2.3 | About Lung Cancer | 30 | 2.4 | Stages of Lung Cancer | 36 | 2.5 | Causes of Lung Cancer | 46 | | LONG LIFE PHARMACEUTICALS PVT. LTD. | | 3.1 | Vision and Mission | 48 | 3.2 | Board of Directors | 49 | 3.3 | Contract Manufacturing | 50 | 3.4 | Suppliers | 53 | 3.5 | Product Range | 56 | 3.6 | Price | 60 | 3.7 | Place | 61 | 3.8 | Promotion | 63 | 3.9 | 5 Force Model | 66 | 4.0 | SWOT Analysis | 69 | 4.1 | PEST Analysis | 71 |
Bibliography: * Drugs & Cosmetics Act, 1940 (for approvals required from Drug Controller General (India) DCGI regarding import, manufacturing, sale and distribution and conducting clinical trials) * Drugs & Cosmetic Rules, 1945 * Indian Patents Act 1970 & Patents (Amendment) Act 2005: (for protecting the brand/ new discovery of drugs) * Factories Act, 1948 (in relation to license for carrying out manufacturing activities)